News

News Center

Jiuzhitang Maker’s second new drug has received implicit approval (Acceptance No.: CXSL2300202) from the National Medical Products Administration for its Investigational New Drug (IND) application, with the intended indication being autoimmune alveolar proteinosis (aPAP).

2023-06-09

Jiuzhitang Maker's second new drug has received implicit approval (Acceptance No.: CXSL2300202) from the National Medical Products Administration for its Investigational New Drug (IND) application. ， Indication: autoimmune pulmonary alveolar proteinosis (aPAP)

Jiuzhitang Maker's Phase II Clinical Trial for Stem Cell Therapy in Immune Alveolar Proteinosis Officially Launches

Jiuzhitang Maker's participation in establishing a key laboratory in Hunan Province has been approved.

Great news! Jiuzhitang Maker's stem-cell therapy for ischemic stroke has entered Phase IIa clinical trials.

Clinical Recruitment: 45 Patients with Ischemic Stroke

Jiuzhitang Maker: China's First Clinical Trial Approved for a Stem-Cell Drug Targeting Autism!

China's first! Jiuzhitang Maker's stem-cell drug for autism officially begins clinical trials.

Jiuzhitang Maker: Research-grade Stem Cells—We Sincerely Invite Distributors to Join Us

Here is the title—h1 placeholder text

Online Message

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Business license